Impact of Malignancy Category on Vancomycin Dosage Requirements in Pediatric Oncology Patients
| Autor: | Tara Higgins, Kyle A Franco |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Dose business.industry medicine.medical_treatment Incidence (epidemiology) 030106 microbiology Liter Hematopoietic stem cell transplantation Malignancy medicine.disease Gastroenterology Surgery Nephrotoxicity 03 medical and health sciences Internal medicine medicine Vancomycin Trough Concentration business medicine.drug |
| Zdroj: | Journal of Pharmacovigilance. |
| ISSN: | 2329-6887 |
| Popis: | Objectives: To determine the dosage of vancomycin in milligrams/kilogram/day (mg/kg/day) required to achieve a trough value of 10 to 20 micrograms/milliliter (mcg/mL) in pediatric patients with differing types of malignancies. Methods: Retrospective review of pediatric patients with hematologic malignancy, solid tumor, or status post autologous or allogeneic hematopoietic stem cell transplantation (HSCT) receiving at least two doses of intravenous vancomycin with at least one evaluable trough concentration. Primary outcome was the dosage of vancomycin required to achieve first therapeutic trough value. Secondary endpoints included dosage requirement by age, proportion of patients achieving goal, incidence of supratherapeutic trough values and nephrotoxicity. Results: Mean dosage requirements were 72.5 [± 2.3] mg/kg/day among patients with hematologic malignancies, 66.5 [± 3.3] mg/kg/day in patients with solid tumors, and 77.3 [± 4.1] mg/kg/day in HSCT patients (p=0.12). Younger patients required significantly increased daily dosages in order to meet their trough goals in the hematologic malignancy and solid tumor groups (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|